Pembrolizumab for Early Triple-Negative Breast Cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear. METHODS: In this phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with previously untreated stage II or stage III triple-negative breast cancer to receive neoadjuvant therapy with four cycles of pembrolizumab (at a dose of 200 mg) every 3 weeks plus paclitaxel and carboplatin (784 patients; the pembrolizumab-chemotherapy group) or placebo every 3 weeks plus paclitaxel and carboplatin (390 patients; the placebo-chemotherapy group); the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. After definitive surgery, the patients received adjuvant pembrolizumab or placebo every 3 weeks for up to nine cycles. The primary end points were a pathological complete response at the time of definitive surgery and event-free survival in the intention-to-treat population. RESULTS: At the first interim analysis, among the first 602 patients who underwent randomization, the percentage of patients with a pathological complete response was 64.8% (95% confidence interval [CI], 59.9 to 69.5) in the pembrolizumab-chemotherapy group and 51.2% (95% CI, 44.1 to 58.3) in the placebo-chemotherapy group (estimated treatment difference, 13.6 percentage points; 95% CI, 5.4 to 21.8; P<0.001). After a median follow-up of 15.5 months (range, 2.7 to 25.0), 58 of 784 patients (7.4%) in the pembrolizumab-chemotherapy group and 46 of 390 patients (11.8%) in the placebo-chemotherapy group had disease progression that precluded definitive surgery, had local or distant recurrence or a second primary tumor, or died from any cause (hazard ratio, 0.63; 95% CI, 0.43 to 0.93). Across all treatment phases, the incidence of treatment-related adverse events of grade 3 or higher was 78.0% in the pembrolizumab-chemotherapy group and 73.0% in the placebo-chemotherapy group, including death in 0.4% (3 patients) and 0.3% (1 patient), respectively. CONCLUSIONS: Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“improvement in overall survival has been reported in unresectable NSCLC patients and TNBC patients treated with anti PD-L1 antibody with chemotherapy”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Schmid et al., 2020
In the citing paper
“Immune checkpoint blockade (ICB) directed against programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) has shown promising results in TNBC4–6, but the overall response rate of ICB is less than 20%7.”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Self-citation
Research works printed but not linked: 1
- Qi C Huang M Haiderali A et al. Association between pathological complete responses and long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant chemotherapy. Presented at the NCCN Annual Conference Orlando March 21–23 2019.
Cited by
Items 301–400 of 1,004
Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC)
Mustafa, M., Abbas, K., Alam, M., Ahmad, W., Moinuddin, M., Usmani, N., Siddiqui, S. A., & Habib, S. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04772-6 · Cited by 67
Rej, R. K., Roy, J., & Allu, S. R. (2024) · Cancers · doi:10.3390/cancers16030552 · Cited by 71
“The first immunotherapy regimens for TNBC were also approved for metastatic disease beginning in 2019 [9] and for early disease in 2021 [10].”
BackgroundIgnatiadis, M., Bailey, A., McArthur, H. L., El-Abed, S., de Azambuja, E., Metzger, O., Chui, S. Y., Dieterich, M., Perretti, T., Shearer-Kang, E., et al. (2025) · JAMA · doi:10.1001/jama.2024.26886 · Cited by 78
Diagnosis, Prognosis, and Treatment of Triple-Negative Breast Cancer: A Review
Jie, H., Ma, W., & Huang, C. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s516542 · Cited by 115
“12 Overall, the mechanism of action underscores the potential of immune checkpoint inhibitors as a transformative approach in the management of TNBC, particularly for patients who have limited treatment options due to the aggressive nature of the disease.”
Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers
El-Aziz, Y. S. A., Spillane, A. J., Jansson, P. J., & Sahni, S. (2021) · Bioscience Reports · doi:10.1042/bsr20204092 · Cited by 61
Chen, L., Li, H., Zhang, H., Yang, H., Qian, J., Li, Z., Ren, Y. T., Wang, S., Fu, P., Yang, H., et al. (2024) · JAMA · doi:10.1001/jama.2024.23560 · Cited by 81
Clinical development of immuno-oncology therapeutics
Wang, J., Chen, Q., Shan, Q., Liang, T., Forde, P. M., & Zheng, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217616 · Cited by 61
Falvo, P., Orecchioni, S., Hillje, R., Raveane, A., Mancuso, P., Camisaschi, C., Luzi, L., Pelicci, P. G., & Bertolini, F. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1818 · Cited by 65
Early stage triple negative breast cancer: Management and future directions
Chaudhary, L. N. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.05.006 · Cited by 60
Saini, K. S., Punie, K., Twelves, C. J., Bortini, S., de Azambuja, E., Anderson, S., Criscitiello, C., Awada, A. H., & Loi, S. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1936494 · Cited by 62
The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
Retecki, K., Seweryn, M., Graczyk‐Jarzynka, A., & Bajor, M. (2021) · Cancers · doi:10.3390/cancers13236012 · Cited by 64
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Tamirisa, N., & Hunt, K. K. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11223-3 · Cited by 55
Metaplastic breast cancer: A review
Thomas, H. R., Hu, B. Y., Boyraz, B., Johnson, A., Bossuyt, V., Spring, L. M., & Jimenez, R. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103924 · Cited by 56
Targeting triple-negative breast cancer: A clinical perspective
POPOVIC, L. S., Matovina-Brko, G., Popovic, M., Punie, K., Cvetanović, A., & Lambertini, M. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028525 · Cited by 66
“The addition of pembrolizumab demonstrated a benefit independent of PD-L1 status with pCR rates being higher in PD-L1-positive patients in both arms [30,31].”
BackgroundShatsky, R. A., Trivedi, M. S., Yau, C. S. F., Nanda, R., Rugo, H. S., Davidian, M., Tsiatis, B., Wallace, A. M., Chien, A. J., Stringer-Reasor, E. M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03267-1 · Cited by 65
“…after blocks A and B, meaning that the vast majority of Immune + patients achieved pCR without receiving anthracycline chemotherapy, instead of the standard-of-care treatments given in the Keynote 522 regimen for triple-negative breast cancer 29 or the ddAC-T regimen for HR + /HER2 − breast cancer.”
Madigan, L. I., Dinh, P., & Graham, J. D. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01314-6 · Cited by 60
Immune-related biomarkers in triple-negative breast cancer
Zhang, J., Tian, Q., Zhang, M., Wang, H., Wu, L., & Yang, J. (2021) · Breast Cancer · doi:10.1007/s12282-021-01247-8 · Cited by 58
Bockstal, M. V., François, A., Altınay, S., Arnould, L., Balkenhol, M. C. A., Broeckx, G., Burgués, O., Colpaert, C., Dedeurwaerdere, F., Dessauvagie, B. F., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00865-z · Cited by 57
Lorusso, G., Wyss, C. B., Kuonen, F., Vannini, N., Billottet, C., Duffey, N., Pineau, R., Lan, Q., Wirapati, P., Barras, D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.aax8933 · Cited by 57
Torres, E. T. R., Ho, W. J., Danilova, L., Tandurella, J. A., Leatherman, J. M., Rafie, C. I., Wang, C., Brufsky, A., LoRusso, P. M., Chung, V. M., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00729-w · Cited by 66
“PD-L1 expression within breast carcinoma has differential predictive value to anti-PD-L1 checkpoint inhibition in the early-and late-stage breast cancer settings 8,9,44–46 .”
Trop2-targeted therapy in breast cancer
Hu, Y., Zhu, Y., Qi, D., Tang, C., & Zhang, W. (2024) · Biomarker Research · doi:10.1186/s40364-024-00633-6 · Cited by 60
“[76].”
Serrano-García, L., Jávega, B., Llombart‐Cussac, A., Gión, M., Pérez-García, J. M., Cortés, J., & Fernández-Murga, M. L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1513421 · Cited by 70
Cottrell, T. R., Lotze, M. T., Ali, A., Bifulco, C. B., Capitini, C. M., Chow, L. Q. M., Cillo, A. R., Collyar, D. E., Cope, L., Deutsch, J. S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010928 · Cited by 69
Schneider, B. P., Jiang, G., Ballinger, T. J., Shen, F., Chitambar, C. R., Nanda, R., Falkson, C. I., Lynce, F. C., Gallagher, C., Isaacs, C. J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01657 · Cited by 57
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Abraham, J. E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., Roberts, A. N., et al. (2024) · Nature · doi:10.1038/s41586-024-07384-2 · Cited by 53
Clinical trials of immunotherapy in triple-negative breast cancer
Howard, F. M., Pearson, A. T., & Nanda, R. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06665-6 · Cited by 58
“The impressive EFS outcomes with platinum and immunotherapy based treatment in KEYNOTE-173 informed the design of the phase III randomized double-blind KEYNOTE-522 trial, which evaluated pembrolizumab versus placebo plus standard neoadjuvant chemotherapy in individuals with early-stage TNBC [90].”
MethodAn update on treatment of penile cancer
Chadha, J. S., Chahoud, J., & Spiess, P. E. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221127254 · Cited by 55
Page, D. B., Broeckx, G., Jahangir, C. A., Verbandt, S., Gupta, R., Thagaard, J., Khiroya, R., Kos, Z., AbdulJabbar, K., Haab, G. A., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6165 · Cited by 108
Platinum-based chemotherapy for early triple-negative breast cancer
Mason, S., Willson, M. L., Egger, S. J., Beith, J. M., Dear, R. F.-G., & Goodwin, A. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014805.pub2 · Cited by 74
Takahashi, M., Cortés, J., Dent, R. A., Pusztai, L., McArthur, H. L., Kümmel, S., Denkert, C., Park, Y. H., Im, S., Ahn, J., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.42107 · Cited by 64
Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy
Benítez, J. C., Remón, J., & Besse, B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3255 · Cited by 60
Zhang, W., Shen, Y., Huang, H., Pan, S., Jiang, J., Chen, W., Zhang, T., Zhang, C., & Ni, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01779 · Cited by 61
Cyclic fasting-mimicking diet in cancer treatment: Preclinical and clinical evidence
Vernieri, C., Ligorio, F., Tripathy, D., & Longo, V. D. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.06.014 · Cited by 60
Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSO Clinical Practice Guideline
Jimenez, R., Abdou, Y. G., Anderson, P. R., Barry, P. N., Bradfield, L., Bradley, J. A., Heras, L. D., Khan, A. J., Matsen, C. B., Rabinovitch, R. A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01747 · Cited by 63
Update on systemic treatment for newly diagnosed inflammatory breast cancer
Chainitikun, S., Saleem, S., Lim, B., Valero, V., & Ueno, N. T. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.08.014 · Cited by 60
Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease
Mittendorf, E. A., Burgers, F. H., Haanen, J. B. A. G., & Cascone, T. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349411 · Cited by 63
Fatima, M., Sheikh, A., Abourehab, M. A. S., & Kesharwani, P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112432 · Cited by 56
“However, regardless of promising results, poor immunogenicity and immunesuppressive TME are unavoidable hurdles of almost all immunotherapies while treating TNBC [183].”
BackgroundKhan, M. B., Du, K., Ai, M.-L., Wang, B., Lin, J., Ren, A., Chen, C., Huang, Z., Qiu, W., Yuan, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1060308 · Cited by 56
“IMPassion130 NCT02425891 2020 Multicentre, Multinational, Randomised (1:1), Double-blind, Placebo-controlled, Phase III Trial 902 (451/451) 55 (46–64)/ 56 (46-65) Atezolizumab VENTANA PD-L1 (SP142) assay IC 1L”
Carter, J. M., Chumsri, S., Hinerfeld, D. A., Ma, Y., Wang, X., Zahrieh, D., Hillman, D. W., Tenner, K., Kachergus, J. M., Brauer, H. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37806-0 · Cited by 55
Xin, Y., Shen, G., Zheng, Y., Guan, Y., Huo, X., Li, J., Ren, D., Zhao, F., Liu, Z., Li, Z., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08997-w · Cited by 55
Predictive biomarkers for personalized medicine in breast cancer
Rodrigues-Ferreira, S., & Nahmias, C. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215828 · Cited by 57
Tsai, K. K., Huang, S., Northey, J. J., Liao, W., Hsu, C., Cheng, L., Werner, M. E., Chuu, C., Chatterjee, C., Lakins, J. N., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00375-0 · Cited by 59
Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies
MacDonald, I., Nixon, N. A., & Khan, O. F. (2022) · Current Oncology · doi:10.3390/curroncol29070378 · Cited by 59
“In this trial, patients with stage II/III TNBC were randomized to receive either pembrolizumab or placebo for eight cycles in the neoadjuvant setting (given concurrently with paclitaxel and carboplatin, followed by anthracycline and cyclophosphamide chemotherapy) [20].”
BackgroundMethodXia, J., Zhang, L., Peng, X., Tu, J., Li, S., He, X., Li, F., Qiang, J., Dong, H., Deng, Q., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3429 · Cited by 56
Bardia, A., Pusztai, L., Albain, K. S., Ciruelos, E., Im, S., Hershman, D. L., Kalinsky, K. M., Isaacs, C. J., Loirat, D., Testa, L., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241248336 · Cited by 64
Emerging clinical applications of single-cell RNA sequencing in oncology
Boxer, E., Feigin, N., Tschernichovsky, R., Darnell, N. G., Greenwald, A., Hoefflin, R., Kovarsky, D., Simkin, D., Turgeman, S., Zhang, L., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01003-3 · Cited by 60
Recent progress in immune evasion mechanisms of triple-negative breast cancer
Yang, Y., & Wang, W. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07370-w · Cited by 63
Boucher, Y., Kumar, A. S., Posada, J. M., Gjini, E., Pfaff, K. L., Lipschitz, M., Lako, A., Duda, D. G., Rodig, S. J., Hodi, F. S., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00197-w · Cited by 53
de Haas, S. L., Slamon, D. J., Martín, M., Press, M. F., Phillips, G. D. L., Lambertini, C., Prat, A., López-Valverde, V., Boulet, T., & Hurvitz, S. A. (2023) · Breast Cancer Research · doi:10.1186/s13058-022-01587-z · Cited by 51
“The observed associations between PD-L1 and clinical outcomes may be related more to their independent prognostic potential than to a relationship with response to HER2-targeted therapeutics, as similar associations have been observed in studies of patients with triple-negative breast cancer [51, 52].”
ResultApplications of Artificial Intelligence in Breast Pathology
Liu, Y., Han, D., Parwani, A. V., & Li, Z. (2023) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2022-0457-ra · Cited by 63
Stecklein, S. R., Kimler, B. F., Yoder, R., Schwensen, K., Staley, J. M., Khan, Q. J., O’Dea, A. P., Nye, L. E., Elia, M., Heldstab, J., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00512-7 · Cited by 56
Wu, S., Zhang, S.-W., Ma, D., Xiao, Y. Q., Liu, Y., Chen, L., Song, X.-Q., Ma, X.-Y., Xu, Y., Chai, W.-J., et al. (2023) · Med · doi:10.1016/j.medj.2023.04.008 · Cited by 57
Litton, J. K., Beck, J. T., Jones, J. M., Andersen, J., Blum, J. L., Mina, L. A., Brig, R., Danso, M. A., Yuan, Y., Abbattista, A., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad139 · Cited by 55
Huang, S., Wen, T., Wang, J., Wei, H., Xiao, Z., Li, B., & Shuai, X. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.01.009 · Cited by 55
Choi, Y., Kim, S. A., Jung, H., Kim, Y. K., Kim, S., Kim, J., Kim, J., Lee, Y., Jo, M. K., Woo, J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008864 · Cited by 60
Zhang, S.-W., Wang, H., Xiao, Y. Q., Liu, L.-T., Shen, M., Wang, Z., Zhao, S., Ding, X.-H., Wang, Y., Zhuang, Q.-Y., et al. (2026) · Cell · doi:10.1016/j.cell.2026.01.001 · Cited by 63
Kyte, J. A., Andresen, N. K., Russnes, H., Fretland, S. Ø., Falk, R. S., Lingjærde, O. C., & Naume, B. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02421-w · Cited by 49
Oligometastatic breast cancer: where are we now and where are we headed?—a narrative review
Kent, C. L., McDuff, S. G. R., & Salama, J. K. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-1128 · Cited by 48
Coloma, C. S., Santaballa, A., Sanmartín, E., Calvo, D. C., García, A., Hervás, D., Cordón, L., Quintás‐Cardama, A., Ripoll, F., Panadero, J., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.08.020 · Cited by 49
Fang, L., Zhao, Z., Wang, J., Xiao, P., Sun, X., Ding, Y., Zhang, P., Wang, D., & Li, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.006 · Cited by 45
Immunotherapy in triple-negative breast cancer: A literature review and new advances
Valencia, G., Rioja, P., Morante, Z., Ruiz, R., Fuentes, H. A., Castañeda, C. A., Vidaurre, T., Neciosup, S. P., & Gómez, H. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i3.219 · Cited by 50
PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
Menezes, M. C. S., Raheem, F., Mina, L. A., Ernst, B. J., & Batalini, F. (2022) · Cancers · doi:10.3390/cancers14174332 · Cited by 54
“Pembrolizumab increased the pCR rate from 51% to 65%, regardless of the presence or absence of PD-L1 expression [117].”
BackgroundThe anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments
Rayson, V., Harris, M. A., Savas, P. S., Hun, M. L., Virassamy, B., Salgado, R., & Loi, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.02.008 · Cited by 53
Colomer, R., González‐Farré, B., Ballesteros, A. I., Peg, V., Bermejo, B., Perez‐Mies, B., de la Cruz, S., Rojo, F., Pernas, S., & Palacios, J. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03541-1 · Cited by 68
“In this setting, the combination of chemotherapy with pembrolizumab (KEY-NOTE-522 trial) has showed evidence of efficacy [58, 59].”
Wu, S., Jin, X., Liu, Y., Wang, Z.-Y., Zuo, W., Ma, D., Xiao, Y., Fu, T., Xiao, Y.-L., Chen, L., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03776-7 · Cited by 62
Deng, S., Chen, Y., Song, B., Wang, H., Huang, S., Wu, K., & Chu, Q. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01754-7 · Cited by 66
Danesi, R., Fogli, S., Indraccolo, S., Re, M. D., Tos, A. P. D., Leoncini, L., Antonuzzo, L., Bonanno, L., Guarneri, V., Pierini, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100040 · Cited by 56
Emerging Therapeutics for Patients with Triple-Negative Breast Cancer
Agostinetto, E., Eiger, D., Punie, K., & de Azambuja, E. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01038-6 · Cited by 48
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.06.001 · Cited by 60
Oshi, M., Newman, S., Murthy, V., Tokumaru, Y., Yan, L., Matsuyama, R., Endo, I., & Takabe, K. (2020) · Cancers · doi:10.3390/cancers12102758 · Cited by 46
Oncobiology and treatment of breast cancer in young women
Kumar, R., Abreu, C., Toi, M., Saini, S., Casimiro, S., Arora, A., Paul, A. M., Velaga, R., Rameshwar, P., Lipton, A., et al. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10034-6 · Cited by 51
“1 3 has been reported to improve pathological response and event-free survival when used as neoadjuvant treatment (followed by post-operative adjuvant) in combination with anthracycline-taxane-platinum chemotherapy in TNBC patients, and thus, it is likely to become a standard treatment in such patients [138].”
BackgroundZheng, J., & Hao, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1333839 · Cited by 54
Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer
Stovgaard, E. S., Kümler, I., List-jensen, K., Roslind, A., Christensen, I. J., Høgdall, E. V. S., Nielsen, D., & Balslev, E. (2021) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000954 · Cited by 47
Interleukin-10: A double-edged sword in breast cancer
Chang, C., Lam, H. Y. P., Hsu, H., & Jiang, S. (2021) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_162_20 · Cited by 53
MicroRNA Expression Profiles and Breast Cancer Chemotherapy
Davey, M. G., Lowery, A., Miller, N., & Kerin, M. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910812 · Cited by 45
Myocardial PD-L1 Expression in Patients With Ischemic and Non-ischemic Heart Failure
Kushnareva, E. A., Kushnarev, V. A., Artemyeva, A. S., Mitrofanova, L. B., & Моисеева, О. М. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.759972 · Cited by 49
Conforti, F., Pala, L., Bagnardi, V., Pas, T. M. D., Colleoni, M. A., Buyse, M. E., Hortobágyi, G. N., Gianni, L., Winer, E. P., Loibl, S., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.3755 · Cited by 49
Immunotherapy in breast cancer: current landscape and emerging trends
Ran, R., Chen, X., Yang, J., & Xu, B. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00667-y · Cited by 67
“Sub-sequently, the phase III KEYNOTE-522 trial demonstrated significant improvements in pCR and EFS with the addition of pembrolizumab to neoadjuvant paclitaxel and carboplatin [60, 61].”
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types
Awada, G., Cascone, T., van der Heijden, M. S., Blank, C. U., Kok, M., & Chalabi, M. (2025) · Nature Cancer · doi:10.1038/s43018-025-00990-7 · Cited by 54
“While most of the described studies have shown encouraging pCR rates, the impact on survival is uncertain, and neoadjuvant immuno-therapy regimens are currently not an SOC for patients with G/GEJ cancers.”
InfluentialExpanding the Role for Immunotherapy in Triple-Negative Breast Cancer
Savas, P. S., & Loi, S. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.007 · Cited by 47
Yuan, Y., Lee, J. S., Yost, S. E., Li, S. M., Frankel, P. H., Ruel, C., Schmolze, D. D., Robinson, K., Tang, A., Martínez, N., et al. (2020) · The Oncologist · doi:10.1002/onco.13574 · Cited by 47
Jia, H., Liu, M., Wang, X., Jiang, Q., Wang, S., Santhanam, R. K., Lv, C., Zhao, Q., & Lu, J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105686 · Cited by 45
Sardesai, S. D., Thomas, A., Gallagher, C., Lynce, F. C., Ottaviano, Y. L., Ballinger, T. J., Schneider, B. P., Storniolo, A. M., Bauchle, A., Althouse, S. K., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0493 · Cited by 51
Iwase, T., Blenman, K., Li, X., Reisenbichler, E., Seitz, R. S., Hout, D. R., Nielsen, T. J., Schweitzer, B. L., Bailey, D. B., Shen, Y., et al. (2021) · Cancers · doi:10.3390/cancers13194839 · Cited by 45
Wang, J., Browne, L. H., Šlapetová, I., Shang, F., Lee, K., Lynch, J., Beretov, J., Whan, R. M., Graham, P., & Millar, E. K. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-01116-6 · Cited by 53
Blenman, K., Marczyk, M., Karn, T., Qing, T., Li, X., Gunasekharan, V. K., Yaghoobi, V., Bai, Y., Ibrahim, E., Park, T., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3215 · Cited by 49
Thompson, K. J., Leon-Ferre, R. A., Sinnwell, J. P., Zahrieh, D., Suman, V. J., Metzger, O., Asad, S., Stover, D. G., Carey, L., Sikov, W. M., et al. (2022) · NAR Cancer · doi:10.1093/narcan/zcac018 · Cited by 48
“pembrolizumab) to cytotoxic chemotherapy has resulted in improvements in progression-free and overall survival in the metastatic setting (among PD-L1-positive tumors) (27,28) and improvements in pathologic complete response and event-free survival in non-metastatic TNBC (regardless of PD-L1 expression) (29).”
BackgroundAdvances in Therapeutic Approaches for Triple-Negative Breast Cancer
Mahtani, R. L., Kittaneh, M., Kalinsky, K. M., Mamounas, E. P., Badve, S., Vogel, C. L., Lower, E. E., Schwartzberg, L. S., & Pegram, M. D. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.12.011 · Cited by 49
Lymph nodes: at the intersection of cancer treatment and progression
Reticker-Flynn, N. E., & Engleman, E. G. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.04.001 · Cited by 47
NR1D1 Stimulates Antitumor Immune Responses in Breast Cancer by Activating cGAS-STING Signaling
Ka, N., Park, M. K., Kim, S.-S., Jeon, Y., Hwang, S., Kim, S. M., Lim, G. Y., Lee, H., & Lee, M. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0329 · Cited by 53
“Recently, pembroli-zumab,ananti – programmeddeath 1mAb,was approved by theFDA for patients with TNBC, expanding treatment options for breast cancer (47).”
Sharma, A., Alexander, G., Chu, J. H., Markopoulos, A., Maloul, G., Ayub, M. T., Fidler, M. J., & Okwuosa, T. M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032620 · Cited by 52
“Studies like Schmid et al 25,26 and Monk et al 84 included mostly female participants only, as the cancers included were breast and ovarian.”
Ho, A. Y., Wright, J. L., Blitzblau, R. C., Mutter, R. W., Duda, D. G., Norton, L., Bardia, A., Spring, L. M., Isakoff, S. J., Chen, J. H., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.05.011 · Cited by 48
Advances in Combining Radiation and Immunotherapy in Breast Cancer
Nguyen, A. T., Shiao, S. L., & McArthur, H. L. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.03.007 · Cited by 48
Hagenaars, S. C., de Groot, S., Cohen, D. B., Dekker, T. J. A., Charehbili, A., Kranenbarg, E. M., Carpentier, M. D., Pijl, H., Putter, H., Tollenaar, R. A. �. �., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33700 · Cited by 56
Breast cancer management in 2021: A primer for the obstetrics and gynecology
Fleege, N. M. G., & Cobain, E. F. (2022) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2022.02.004 · Cited by 52
Liu, S., Gao, W., Ning, Y., Zou, X., Zhang, W., Zeng, L., & Liu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908173 · Cited by 55
Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
Luque, M., Sanz-Álvarez, M., Morales-Gallego, M., Madoz‐Gúrpide, J., Zazo, S., Domínguez, C., Cazorla, A., Izarzugaza, Y., Arranz, J. L., Cristóbal, I., et al. (2022) · Cancers · doi:10.3390/cancers14246034 · Cited by 52
“The immune checkpoint inhibitors atezolizumab and pembrolizumab, both PD-1/PDL1 axis inhibitors, have been recently approved by the FDA for the treatment of unresectable, locally advanced or metastatic TN breast cancer [111,112].”
BackgroundHow I treat HER2-low advanced breast cancer
Schlam, I. M., Tolaney, S. M., & Tarantino, P. (2023) · The Breast · doi:10.1016/j.breast.2023.01.005 · Cited by 48
“Program cell death ligand expression (PDL1) by the Dako 22C3 assay should be assessed at diagnosis; patients with a combined positive score ≥10 are candidates for first-line treatment with pembrolizumab in combination with chemotherapy [50].”
BackgroundDent, R. A., Cortés, J., Pusztai, L., McArthur, H. L., Kümmel, S., Bergh, J. C. S., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae129 · Cited by 55
Lu, X., Gou, Z., Chen, H., Li, L., Chen, F., Bao, C., Bu, H., & Zhang, Z. (2025) · The Journal of Pathology · doi:10.1002/path.6395 · Cited by 59
“Recent clinical trials have shown that immune checkpoint inhibitor (ICI) therapy can improve survival and provide durable bene fi ts for TNBC patients [2,3].”
Metadata
- Authors
- Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Foukakis, T., Fasching, P. A., Cardoso, F., Untch, M., Jia, L., Karantza, V., Zhao, J., Aktan, G., Dent, R., & O’Shaughnessy, J.
- Affiliations
- Queen Mary University of London (GB)
- IOB Institute of Oncology, Quiron Group;Vall d’Hebron Institute of Oncology (VHIO), Madrid & Barcelona, Spain
- Yale Cancer Center (US)
- Cedars-Sinai Medical Center (US)
- Kliniken Essen-Mitte (DE)
- Karolinska University Hospital (SE)
- Philipps University of Marburg (DE)
- Samsung Medical Center (KR)
- The University of Sydney (AU)
- Ludwig-Maximilians-Universität München (DE)
- Sapporo National Hospital (JP)
- Universitätsklinikum Erlangen (DE)
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
- Helios Hospital Berlin-Buch (DE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- National University of Singapore (SG)
- Baylor University Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-27
- Volume
- 382
- Issue
- 9
- Pages
- 810-821
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3006930853
- Cited by
- 3,270
- References
- 31
- Citations by year
- 2026: 580 · 2025: 576 · 2024: 552 · 2023: 500 · 2022: 514 · 2021: 391 · 2020: 152
- FWCI
- 133.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (N/A)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
- Keywords
- pembrolizumab, triple-negative breast cancer, early breast cancer, neoadjuvant immunotherapy, neoadjuvant chemotherapy, paclitaxel, carboplatin, pathological complete response, event-free survival, immune checkpoint inhibitors, doxorubicin-cyclophosphamide, epirubicin-cyclophosphamide
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Female, Humans, Middle Aged, Neoplasm Staging, Epirubicin, Carboplatin, Paclitaxel, Neoadjuvant Therapy, Kaplan-Meier Estimate, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.